Posted by Michael Wonder on 01 Jun 2018
New analysis shows using ICER’s value assessments would limit access to life-saving medicines in Medicare Part B
31 May 2018 - 62 to 93% of Medicare Part B beneficiaries with serious, complex conditions could lose access to their medicines.
If Medicare were to utilize one-size-fits-all value assessments like the ICER's framework as the basis for coverage, 62 to 93% of patients with serious, complex conditions would face access barriers to life-saving medicines, according to a new analysis from Xcenda.
“The science of value assessment is not keeping pace with innovation, and we need better tools to measure the value of medicines,” said Stephen J. Ubl, president and CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA). “We support advancing these tools from being focused on rigid, budget driven methodologies toward more flexible approaches that include perspectives of what patients value.”
